Miltuximab® for Therapeutics and Imaging

Our patented antibody targets Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors.

We have completed a first in human trial using Miltuximab®, our anti-GPC-1 monoclonal antibody (ANZCTR registry).

The trial was a first-in-human study to evaluate the safety and tumor targeting of Miltuximab® in patients with advanced prostate, bladder and pancreatic cancer. Preclinical studies demonstrated that Miltuximab® accurately targets prostate, pancreatic and bladder cancer cells and is well-tolerated and highly specific in mouse models of prostate cancer.

The trial was conducted at the Macquarie University Hospital and involved experts from the Australian Nuclear Science and Technology Organisation (ANSTO), Catalent, AusPep, and Southern Star Research.

In July 2018 the Company announced that it has completed enrolment and dosing of all 12 patients in its pioneering clinical trial and was pleased to report Miltuximab® was well tolerated with no drug related adverse events reported by any of the 12 patients.

Glytuzumab® refers to the humanized version of Miltuximab® and also targets human GPC-1. The Glytuzumab® program is currently undergoing Lead Optimisation and Lead Selection stages. Several humanized leads have been generated with similar binding affinities as that of the parent molecule Miltuximab®. The final Glytuzumab® lead selected will be taken forward from cell line development through to large scale GMP production for future clinical trials.

In addition to radiotherapy, GlyTherix is looking at other mechanisms of action using Miltuximab®

Global research collaborations

GlyTherix’s collaborations are advancing trials of prostate cancer therapeutics, and imaging as well as building a future product pipeline.

For example:

  • The Centre for Advanced Imaging at the University of Queensland
  • The Australian Prostate Cancer Research Centre at the Queensland University of Technology
  • The IDEAL Hub, University of Technology Sydney and University of South Australia
  • The Division of Urologic Oncology at the University of Michigan Medical School
  • Molecular Imaging Innovations Institute at Weill Cornell Medical College New York

Learn more about the therapeutic opportunities for Miltuximab® in prostate, pancreatic, bladder, esophageal and other solid tumors – click here.

Privacy Policy